Journal of Thrombosis and Thrombolysis

Papers
(The TQCC of Journal of Thrombosis and Thrombolysis is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
COVID-19 update: Covid-19-associated coagulopathy480
Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum318
COVID-19-associated vasculitis and vasculopathy213
COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature189
Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors180
Neutrophil extracellular traps and thrombosis in COVID-19179
Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia153
Heparin resistance in COVID-19 patients in the intensive care unit129
The association between treatment with heparin and survival in patients with Covid-19126
Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients120
Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis114
Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis84
Anticipating the long-term cardiovascular effects of COVID-1979
Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-1974
COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness68
Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients64
Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis64
High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there?62
Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy60
Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review60
Anticoagulant treatment in COVID-19: a narrative review59
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE58
Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-1958
DVT incidence and risk factors in critically ill patients with COVID-1958
Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients53
Risk factors for intracerebral hemorrhage in patients with COVID-1949
COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis41
Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-1940
Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-1940
Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis40
COVID-19: Are we dealing with a multisystem vasculopathy in disguise of a viral infection?38
Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-1938
Incidence of thrombotic complications in COVID-1937
In vivo demonstration of microvascular thrombosis in severe COVID-1936
Pulmonary thrombosis in Covid-19: before, during and after hospital admission36
Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series36
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis34
Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting33
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum33
Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus32
Stress hyperglycemia is predictive of worse outcome in patients with acute ischemic stroke undergoing intravenous thrombolysis32
Major bleeding complications in critically ill patients with COVID-19 pneumonia31
Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis30
The administration of rtPA before mechanical thrombectomy in acute ischemic stroke patients is associated with a significant reduction of the retrieved clot area but it does not influence revasculariz30
Rotational thromboelastometry results are associated with care level in COVID-1930
Immature platelets in patients hospitalized with Covid-1929
Ovarian vein thrombosis after coronavirus disease (COVID-19) infection in a pregnant woman: case report29
SARS-CoV-2 infection and thrombotic complications: a narrative review28
Rate of venous thromboembolism in a prospective all-comers cohort with COVID-1927
Safety of intermediate dose of low molecular weight heparin in COVID-19 patients27
Impact of the COVID-19 pandemic on hyperacute stroke treatment: experience from a comprehensive stroke centre in Singapore27
COVID-19 and its sequelae: a platform for optimal patient care, discovery and training26
Thromboelastography findings in critically ill COVID-19 patients25
Impact of Coronavirus Disease 2019 outbreak on acute coronary syndrome admissions: four weeks to reverse the trend25
Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines25
Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products25
Successful use of tPA for thrombolysis in COVID related ARDS: a case series24
Sudden death due to acute pulmonary embolism in a young woman with COVID-1924
Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy24
Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic23
Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation23
Aortic thrombus in patients with severe COVID-19: review of three cases22
Value-based assessment of implementing a Pulmonary Embolism Response Team (PERT)21
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage21
Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-1920
External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-1920
Increased intracranial hemorrhage of mechanical thrombectomy in acute ischemic stroke patients with atrial fibrillation20
A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines20
Evidence of systemic endothelial injury and microthrombosis in hospitalized COVID-19 patients at different stages of the disease19
Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation19
A comprehensive review of vascular complications in COVID-1919
Serotonin: a platelet hormone modulating cardiovascular disease19
Markers of coagulation dysfunction and inflammation in diabetic and non-diabetic COVID-1919
Lupus anticoagulant and mortality in patients hospitalized for COVID-1918
Arterial and venous involvement in Behçet’s syndrome: a narrative review18
Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?18
Thrombosis in VEXAS syndrome18
High prevalence of early asymptomatic venous thromboembolism in anticoagulated COVID-19 patients hospitalized in general wards18
Filter clotting with continuous renal replacement therapy in COVID-1918
Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?17
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials17
CHA2DS2-VASc score and modified CHA2DS2-VASc score can predict mortality and intensive care unit hospitalization in COVID-19 patients17
Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design17
Clinical features of patients with acute coronary syndrome during the COVID-19 pandemic17
Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data17
Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study)17
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis16
Significant reductions in apoptosis-related proteins (HSPA6, HSPA8, ITGB3, YWHAH, and PRDX6) are involved in immune thrombocytopenia15
Hyperacute multi-organ thromboembolic storm in COVID-19: a case report15
Clinical significance of healed plaque detected by optical coherence tomography: a 2-year follow-up study15
Thromboembolic complications of recreational nitrous oxide (ab)use: a systematic review15
Acute pulmonary embolism in COVID-19 related hypercoagulability15
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-1915
Functional testing of tranexamic acid effects in patients undergoing elective orthopaedic surgery15
Global haemostatic tests in rapid diagnosis and management of COVID-19 associated coagulopathy in acute limb ischaemia15
Association between vitamin D deficiency and serum Homocysteine levels and its relationship with coronary artery disease15
Role of rivaroxaban in sunitinib-induced renal injuries via inhibition of oxidative stress-induced apoptosis and inflammation through the tissue nacrosis factor-α induced nuclear factor-κappa B signal14
Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 201914
Should we consider heparin prophylaxis in COVID-19 patients? a systematic review and meta-analysis14
Roles of factor Xa beyond coagulation14
Association of ABO blood group type with cardiovascular events in COVID-1914
A case of thrombotic thrombocytopenic purpura associated with COVID-1914
Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate14
Global epidemiology of venous thromboembolism in people with active tuberculosis: a systematic review and meta-analysis14
ST-segment elevation in patients with COVID-19: a systematic review14
Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics14
Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome13
Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis13
Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies13
Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-1913
Circadian variations in pathogenesis of ST-segment elevation myocardial infarction: an optical coherence tomography study13
Occurrence of pulmonary embolism related to COVID-1913
COVID 19 infection associated with thrombotic thrombocytopenic purpura13
Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis13
Platelet microvesicles are associated with the severity of coronary artery disease: comparison between peripheral and coronary circulation13
Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysis13
Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population13
Prior use of anticoagulation is associated with a better survival in COVID-1912
Association of chronic anticoagulant and antiplatelet use on disease severity in SARS-COV-2 infected patients12
The clinical characteristic, diagnosis, treatment, and prognosis of cerebral cortical vein thrombosis: a systematic review of 325 cases12
Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis12
Pulmonary Embolism Response Team activation during the COVID-19 pandemic in a New York City Academic Hospital: a retrospective cohort analysis12
One-year outcomes of patients with ST-segment elevation myocardial infarction during the COVID-19 pandemic12
PEAR1 polymorphisms as a prognostic factor in hemostasis and cardiovascular diseases12
Mitochondria and chronic effects of cancer therapeutics: The clinical implications12
HIT in the head: a systematic review of cerebral venous sinus thrombosis in classical and autoimmune heparin-induced thrombocytopenia12
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor12
Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism11
Incidence of venous thromboembolism among patients with severe COVID-19 requiring mechanical ventilation compared to other causes of respiratory failure: a prospective cohort study11
Impact of the pandemic of COVID-19 on emergency attendance for stroke and acute myocardial infarction in Beijing, China11
Reducing state attenuates ectodomain shedding of GPVI while restoring adhesion capacities of stored platelets: evidence addressing the controversy around the effects of redox condition on thrombosis11
Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection11
Excessive fibrinolysis detected with thromboelastography in a case of amniotic fluid embolism: fibrinolysis may precede coagulopathy11
Risk factors of postoperative deep vein thrombosis (DVT) under low molecular weight heparin (LMWH) prophylaxis in patients with thoracolumbar fractures caused by high-energy injuries11
Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients11
Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score11
COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography11
Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertension11
LncRNA LSINCT5/miR-222 regulates myocardial ischemia‑reperfusion injury through PI3K/AKT pathway11
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes11
Combining lung ultrasound and Wells score for diagnosing pulmonary embolism in critically ill COVID-19 patients11
Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis11
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone10
Global coagulation assays in hypercoagulable states10
Treatment of platelet concentrates with the L-carnitine modulates platelets oxidative stress and platelet apoptosis due to mitochondrial reactive oxygen species reduction and reducing cytochrome C rel10
Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management10
Global coagulation assays in healthy controls: are there compensatory mechanisms within the coagulation system?10
Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case–control study10
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study10
Neurological manifestations of thrombotic microangiopathy syndromes in adult patients10
Immature platelets in patients with Covid-19: association with disease severity10
COVID-19 and biomarkers of thrombosis: focus on von Willebrand factor and extracellular vesicles10
Circ_0003204 knockdown protects endothelial cells against oxidized low-density lipoprotein-induced injuries by targeting the miR-491-5p-ICAM1 pathway10
0.078983068466187